Semaglutide in Perimenopause: What to Know

Still cycling, but everything feels like it is changing

You are still getting your period, so you keep thinking this is not supposed to be happening yet. But your cycles have gone unpredictable, closer together one month, skipped the next, heavier, then spotting. In the couple of weeks before a period you are ravenous and the food noise is deafening, and then some weeks it eases. The scale is creeping up, mostly around your middle. You have read plenty about menopause weight gain, and a quiet voice keeps saying, I am not in menopause yet, I am still cycling, so does any of that even apply to me? Is it too early for something like semaglutide in perimenopause?

You are not imagining it, and it is not too early. Perimenopause is a distinct, often multi-year window before your final period, and its defining feature is that hormones fluctuate erratically rather than settling into a smooth decline. That fluctuation is what is driving the changes you are noticing.

One thing to be clear about up front. GLP-1 medications are not approved to treat perimenopause. Some are FDA-approved for chronic weight management in certain adults. Nothing on this page describes them as a hormone treatment or a fix for perimenopause symptoms. This page explains what perimenopause does to weight and appetite while you are still cycling, where GLP-1 weight management fits, and the two things that matter specifically because you can still conceive: contraception and fertility.

Perimenopause is not menopause: the transition years, still cycling

It helps to be precise about the words, because they get used interchangeably and they are not the same thing. Perimenopause is the transition leading up to menopause, the years when your ovaries are winding down but have not stopped. Menopause itself is a single point in time: twelve months with no period at all. Everything before that is perimenopause.

That distinction is the whole point of this page. Perimenopause commonly begins in your forties, though it can start in your late thirties, and it often lasts several years. During that window you are still menstruating, even if the timing is all over the place. You are still ovulating at least some cycles. And that means you can still be able to conceive.

This is what separates the transition from the settled state that comes after. The menopause weight gain picture, once estrogen has declined and periods have stopped, is a steadier one: a lower hormonal baseline your body has largely adjusted to. Perimenopause is the messier lead-up, when the hormones are still swinging and your reproductive system is still active. If you want the full picture of what happens after the transition, that companion page covers it. This page stays with the window you are in now, because being still cycling changes what matters, both for how your weight behaves and for two practical considerations most articles skip.

Why estrogen fluctuates, not just declines, and why that changes your weight and appetite

Here is the piece that gets lost when perimenopause is lumped in with menopause. During the transition, estrogen does not fall in a straight line. It swings. Some cycles it spikes higher than it did in your thirties, then crashes low before the next period, then does something different the following month. It is a rollercoaster, not a downhill slope. Those unpredictable swings are exactly why the changes feel so inconsistent: some weeks you feel like yourself, and some weeks you do not.

Those swings show up on the scale and in your appetite even while you are still cycling. A study published in the International Journal of Obesity followed women who started out premenopausal for four years. Those who reached menopause during the study gained visceral fat, the deeper fat around your organs, and had a larger drop in sleeping energy expenditure than women who stayed premenopausal.^[2] Data from the Study of Women’s Health Across the Nation (SWAN), published in JCI Insight, found that at the start of the transition the rate of fat gain doubled and lean mass began to decline, years before the final period.^[3] In other words, the shift toward midsection fat and away from muscle begins in perimenopause, while periods are still happening. The full mechanism of how this settles out is covered on the menopause weight gain page; what matters here is that it starts now.

There is also the appetite side, and this is where you may recognize yourself. The intrusive, hard-to-ignore food thoughts you may know as food noise can track the erratic cycle, spiking in the back half when hormones are crashing and easing when they steady. Add the disrupted sleep that is common in perimenopause, which is itself linked to stronger appetite and cravings, and you get a moving target. A review in the journal Climacteric concluded that the hormonal changes across perimenopause contribute substantially to increased abdominal fat, even though overall midlife weight gain cannot be blamed on menopause alone.^[1] The food noise that comes and goes is not a willpower dip. It is your biology recalibrating in real time.

Where GLP-1 weight management fits during perimenopause, and where it does not

Here is the honest boundary. GLP-1 medications are not a treatment for perimenopause. They do not replace or regulate estrogen, and they are not hormone therapy. Do not expect them to help with hot flashes, mood swings, sleep disruption, or anything about your cycle. What they do is act on appetite and digestion.

GLP-1 medications reduce appetite and slow how quickly your stomach empties, which for many people quiets the constant food noise and makes a smaller, steadier intake feel manageable rather than like a fight. When the hormonal swings of perimenopause have pushed your appetite around and tilted the intake side of the equation against you, that mechanism addresses one specific piece of the picture. It does not touch the hormones themselves. It works on the hunger and food-noise signaling that the hormones have amplified.

That is the accurate way to frame semaglutide in perimenopause, and the limits matter. A GLP-1 is a weight management tool a provider may consider as part of a broader plan, not a fix for the transition and not a standalone answer. Because muscle and bone matter more than ever in this stage, that broader plan includes how you eat while your appetite is smaller. We keep the nutrition tactics on a dedicated page rather than repeating them here; see how to eat on a GLP-1 in perimenopause for the specifics on protein, bone, and steady energy.

Because you are still cycling: birth control and fertility

This is the part the settled-menopause articles cannot address, because it only applies while you are still cycling. Two label points are worth knowing, and both end the same way: raise them with your prescriber.

Birth control. If you rely on the pill, this matters, and it depends on the medication. The Zepbound (tirzepatide) label warns that tirzepatide may make oral hormonal contraceptives less effective because it slows stomach emptying, with the largest effect after the first dose. It says to switch to a non-oral method, or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.^[7] The Wegovy (semaglutide) label does not include this instruction and lists no clinically significant change in the pill hormones it tested.^[6] That is a label point, not a reason to stop anything on your own or to assume your birth control will fail. The right move is simply to tell your prescriber what you use so it can be factored into the plan. We walk through the details in our guide on how GLP-1 medications can affect oral birth control. We are not recommending a specific method or dose here; that is a conversation for you and your provider.

Fertility and pregnancy. GLP-1 medications are not used during pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy because of semaglutide’s long half-life.^[6] The Zepbound label says to stop when a pregnancy is recognized and does not list a specific washout period.^[7] Because you may still be able to conceive in perimenopause, even with irregular cycles, this matters even if another pregnancy is not the plan. If pregnancy is a possibility for you, that belongs in the conversation with your prescriber. Our guide on GLP-1 medications and fertility covers the guidance in more detail. Again, this is label information to discuss with your prescriber, not medical advice about your specific situation.

None of this is a reason for alarm. It is the opposite: honest information about the still-cycling reality that the after-the-fact menopause page cannot speak to, so you can raise the right things at the right time.

What the research shows

The large clinical trials behind GLP-1 medications were conducted with FDA-approved branded products, and what they actually tested matters here.

In the STEP 1 trial, published in the New England Journal of Medicine, adults with overweight or obesity who received semaglutide 2.4 mg (the medication in Wegovy) for weight management lost significantly more weight than those on placebo over 68 weeks, alongside lifestyle support.^[4] In the SURMOUNT-1 trial, also in the New England Journal of Medicine, adults with obesity or overweight who received tirzepatide (the medication in Zepbound) for weight management saw substantial reductions in body weight compared with placebo over 72 weeks.^[5] Nausea, diarrhea, and other digestive side effects were the most common adverse events in both trials, mostly mild to moderate, and some participants stopped treatment because of them.^[4][5] Neither trial was designed to study perimenopause specifically, so they tell you how the medications performed in a broad adult population, not what happens for you based on where you are in the transition.

What the trials do not tell you is exactly what will happen for you. Results vary. Trial results describe study participants and are not a prediction for any individual. Outcomes depend on many factors, including your starting point, your health history, and the nutrition and activity plan around the medication. A licensed provider can help you understand what a realistic outcome looks like for your situation.

One critical clarification about what these findings apply to. Every result described above comes from FDA-approved brand-name products. Some telehealth programs prescribe compounded semaglutide or tirzepatide instead. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review them for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency. The trial data is evidence about the brand-name medications tested, not a promise about a compounded product.

How the process should work

At most telehealth programs, a licensed provider reviews your health history, including where you are in the transition, your current medications such as contraception or hormone therapy if you use it, your labs where available, and your goals, and decides whether a prescription is appropriate. If you have started hormone therapy for symptoms, as some perimenopausal women do, that is relevant information for any prescriber considering a GLP-1. Hormone therapy and a GLP-1 are often prescribed by different providers, so make sure each one knows everything you take, and ask your prescriber how the two fit together for you.

Being in perimenopause does not by itself qualify or disqualify you. The FDA-approved weight-management indications are based on BMI and weight-related conditions, not on menstrual status. That is a medical decision, not an automatic approval. If you are comparing programs, ask:

• Will the prescriber ask about pregnancy plans and birth control? A careful intake should cover both, given the label instructions above.
• Will they ask about hormone therapy and your other medications? Your full medication list matters for any prescription.
• Are labs included or billed separately? Some programs include baseline labs; others bill separately or ask you to get them through your own provider.
• What support comes with the prescription? Some programs include nutrition or strength-training guidance; others do not. Protein and resistance training matter for protecting muscle at this stage, so know what you are getting.

Talk about how long you might stay on medication and what happens if you stop. Our guide on stopping weight loss medication covers what to expect.

Transformation Health does not accept payment from providers. How we make money.

What to check before using a GLP-1 medication

Programs differ in what they prescribe and what they charge. A few things to confirm:

• Brand-name or compounded? Some programs prescribe FDA-approved brand-name medications such as Wegovy (semaglutide) or Zepbound (tirzepatide). Others prescribe compounded semaglutide or tirzepatide, prepared by state-licensed compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review them for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency.
• Does the trial evidence apply? Clinical trial data on safety and effectiveness apply to the brand-name products studied in those trials, not to compounded versions.
• What is the total cost? Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
• Which medication, dose, and form? A licensed provider decides which medication and dose, if any, is appropriate for you.

How to get started

For background on how prescribing works, see How getting a GLP-1 prescription works and the GLP-1 Eligibility Guide, which explains the usual qualification criteria.

If PCOS or insulin resistance is also part of your history, our guide on GLP-1 and PCOS covers another hormone-driven weight condition GLP-1 medications are used to address, one of several topics in our guide to GLP-1 and specific health conditions. If protecting muscle through this stage is on your mind, our guide on protecting muscle and body composition covers that too.

Citations

[1] Davis SR, Castelo-Branco C, Chedraui P, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. PMID: 22978257.

[2] Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. “Increased visceral fat and decreased energy expenditure during the menopausal transition.” International Journal of Obesity. 2008;32(6):949-958. PMID: 18332882.

[3] Greendale GA, Sternfeld B, Huang M, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. PMID: 30843880.

[4] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024.

[6] Novo Nordisk. Wegovy (semaglutide) prescribing information. US Food and Drug Administration. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Sections 8.1 and 8.3: stop at least 2 months before a planned pregnancy; section 12.3: no clinically significant change in ethinyl estradiol or levonorgestrel.)

[7] Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Sections 8.1 and 8.3: stop when pregnancy is recognized; oral hormonal contraceptive instructions; section 12.3: contraceptive interaction study.)